2-二氯甲基-4,5-二氢噻唑-4-羧酸甲酯 | 321371-28-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-二氯甲基-4,5-二氢噻唑-4-羧酸甲酯
• 英文名称: methyl 2-(dichloromethyl)-4,5-dihydro-1,3-thiazole-4-carboxylate
• CAS: 321371-28-2
• 化学式: C₆H₇Cl₂NO₂S
• 分子量: 228.099
• InChiKey: FYXOIXUWMFLUTC-UHFFFAOYSA-N

物化性质

• 沸点：
  264.8±40.0 °C(Predicted)
• 密度：
  1.61±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  64
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-二氯甲基-4,5-二氢噻唑-4-羧酸甲酯 在 sodium methylate 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 3.0h， 生成 2-chloromethylthiazole-4-carboxylic acid
  参考文献：
  名称：

  Incorporation of Heterocycles into the Backbone of Peptoids to Generate Diverse Peptoid-Inspired One Bead One Compound Libraries

  摘要：

  Combinatorial libraries of peptoids (oligo-N-substituted glycines) have proven to be useful sources of protein ligands. Each unit of the peptoid oligomer is derived from 2-haloacetic acid and a primary amine. To increase the chemical diversity available in peptoid libraries, we demonstrate here that heterocyclic halomethyl carboxylic acids can be employed as backbone building blocks in the synthesis of peptoid-based oligomers. Optimized conditions are reported that allow the creation of large, high quality combinatorial libraries containing these units.

  DOI：

  10.1021/co200195t
• 作为产物：
  描述：

  二氯乙腈 、 2-氨基-3-疏基丙酸甲酯盐酸盐 在 sodium methylate 作用下， 反应 12.0h， 生成 2-二氯甲基-4,5-二氢噻唑-4-羧酸甲酯
  参考文献：
  名称：

  Incorporation of Heterocycles into the Backbone of Peptoids to Generate Diverse Peptoid-Inspired One Bead One Compound Libraries

  摘要：

  Combinatorial libraries of peptoids (oligo-N-substituted glycines) have proven to be useful sources of protein ligands. Each unit of the peptoid oligomer is derived from 2-haloacetic acid and a primary amine. To increase the chemical diversity available in peptoid libraries, we demonstrate here that heterocyclic halomethyl carboxylic acids can be employed as backbone building blocks in the synthesis of peptoid-based oligomers. Optimized conditions are reported that allow the creation of large, high quality combinatorial libraries containing these units.

  DOI：

  10.1021/co200195t

文献信息

• [EN] FARNESOID X RECEPTOR AGONISTS<br/>[FR] AGONISTES DU RÉCEPTEUR DE FARNÉSOÏDE X
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009005998A1

  公开（公告）日：2009-01-08

  The present invention relates to famesoid X receptors (FXR, NR1H4) FXR is a member of the nuclear receptor class of ligand-activate transcription factors More particularly, the present invention relates to compounds useful as agonists for FXR, pharmaceutical formulations comprising such compounds, and therapeutic use of the same Novel isoxazole compounds are disclosed as part of pharmaceutical compositions for the treatment of a condition mediated by decreased FXR activity, such as obesity, diabetes, cholestatic liver disease, liver fibrosis, and metabolic syndrome

  本发明涉及法内索德X受体（FXR，NR1H4）。FXR是配体激活的转录因子核受体类的一个成员。更具体地说，本发明涉及作为FXR激动剂的化合物，包含该化合物的药物制剂，以及同一治疗用途。新颖的异恶唑化合物被披露作为药物组合物的一部分，用于治疗由FXR活性降低介导的状况，如肥胖、糖尿病、胆汁淤积性肝病、肝纤维化和代谢综合征。
• LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS
  申请人：InterMune, Inc.

  公开号：US20140213538A1

  公开（公告）日：2014-07-31

  Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.

  本发明提供了化合物、制备这种化合物的方法、包含这种化合物的制药组合物和药物，以及使用这种化合物治疗、预防或诊断与一种或多种溶血磷脂酸受体相关的疾病、疾病、或病况的方法。
• FARNESOID X RECEPTOR AGONISTS
  申请人：Akwabi-Ameyaw Adwoa

  公开号：US20110034507A1

  公开（公告）日：2011-02-10

  The present invention relates to farnesoid X receptors (FXR, NR1H4). FXR is a member of the nuclear receptor class of ligand-activate transcription factors. More particularly, the present invention relates to compounds useful as agonists for FXR, pharmaceutical formulations comprising such compounds, and therapeutic use of the same. Novel isoxazole compounds are disclosed as part of pharmaceutical compositions for the treatment of a condition mediated by decreased FXR activity, such as obesity, diabetes, cholestatic liver disease, liver fibrosis, and metabolic syndrome.

  本发明涉及法尼索德X受体（FXR，NR1H4）。FXR是配体激活转录因子的核受体类成员。更具体地，本发明涉及作为FXR激动剂有用的化合物，包含这些化合物的制药组合物以及其治疗用途。新型异唑咪唑化合物被揭示为用于治疗由FXR活性降低介导的疾病状态的制药组合物，例如肥胖症、糖尿病、胆汁淤积性肝病、肝纤维化和代谢综合征。
• [EN] LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RÉCEPTEUR DE L'ACIDE LYSOPHOSPHATIDIQUE
  申请人：INTERMUNE INC

  公开号：WO2014113485A1

  公开（公告）日：2014-07-24

  Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the Iysophosphatidic acid receptors are provided.
• Incorporation of Heterocycles into the Backbone of Peptoids to Generate Diverse Peptoid-Inspired One Bead One Compound Libraries
  作者：Animesh Aditya、Thomas Kodadek

  DOI：10.1021/co200195t

  日期：2012.3.12

  Combinatorial libraries of peptoids (oligo-N-substituted glycines) have proven to be useful sources of protein ligands. Each unit of the peptoid oligomer is derived from 2-haloacetic acid and a primary amine. To increase the chemical diversity available in peptoid libraries, we demonstrate here that heterocyclic halomethyl carboxylic acids can be employed as backbone building blocks in the synthesis of peptoid-based oligomers. Optimized conditions are reported that allow the creation of large, high quality combinatorial libraries containing these units.